Nanomed Devices, Inc. (Nanomed), founded in 2005, incorporated in Delaware, and based in Albany, NY, is a clinical-stage medical product company focusing on developing and commercializing non-invasive drug delivery technology. Nanomed's transdermal device technology is designed to safely and more effectively deliver drugs, including protein drugs that, until now, must be delivered by needle injection. It has a fully owned subsidiary in China where Nanomed has established high-quality, low-cost product development and manufacturing capability.

Nanomed's founders include former employees from the world leader of point-of-care medical device, i-STAT, experienced entrepreneurs and executives, seasoned scientists and engineers, each with more than 20 years of experience in the development and commercialization of medical products. Nanomed successfully conducted a full scale human clinical trial for validating the clinical utilities of its proprietary Functional MicroArray(FMA) drug delivery device, leading to SFDA approval of the product. The company successfully completed the Series A institutional funding to support its rapid growth.

Nanomed's business strategy is to focus initially on two key therapeutic areas: the $5 billion neuropathic pain management market and $7 billion insulin delivery market. Nanomed is partnering with companies and planning to first lauch its product in emerging markets such as China. This approach is clearly less expensive, and offers lower risk and the potential for high return.

Corporate Governance